Middleton, United States
Imbed Biosciences Inc., founded in 2012, is a privately held medical device company positioned as a leader in the development of advanced synthetic therapies for soft-tissue repair and regeneration. With its headquarters in the United States, Imbed operates at the intersection of Biotechnology and Health Care.
The company's portfolio is based on its patented Microlyte® technology, addressing critical needs in surgical wounds, burns, and chronic ulcers. As a registered U.S. FDA medical device manufacturer, Imbed maintains an ISO 13485 certified Quality Management System, underscoring its commitment to quality and regulatory compliance.
In its latest financing round, Imbed secured a $10.00M Convertible Note investment from Pegasus Tech Ventures and Niterra Ventures on 08 January 2024. This funding enables further product development and market expansion, making Imbed a compelling opportunity for investors looking to capitalize on innovations in healthcare technology.
